TOP

Manager

Chairman

ed033ec3daa20476b7c94dcf4e00b910.jpg

Mr. Tse Ping


Mr. Tse Ping is the Founder and Chairman of the CP Pharmaceutical Group. He is responsible for the overall operations of the Group. Mr. Tse has more than 29 years of extensive experience in investment and management in the pharmaceutical industry in China. Mr. Tse is the founding chairman of Sino Biopharmaceutical Limited and now serves as the senior vice chairman of the Board, an executive director, and a member of the executive board committee of the Company. Mr. Tse is currently a director of CT Tianqing, Beijing Tide, NJCTT, Jiangsu CT Fenghai, Jiangsu CT Qingjiang, and CP Qingdao, and the president of Chia Tai Pharmaceutical Investment (Beijing) Co., Ltd. He is also a senior vice president of Chia Tai Group, the president of CP Pharmaceutical Group, and a director of Shanghai Fortune World Development Co., Ltd., Tianjin Chiatai Feed Tech Co., Ltd., SYN Energy Technology Co., Ltd., and Chia Tai Oversea Chinese Realty Development Co., Ltd. Mr. Tse still serves as a director of Chia Tai Qingchunbao Pharmaceutical Co., Ltd. and a council member of the Association of Pharmaceutical Biotechnology of China.


Soon after the adoption of the open-up and reform policy by China, Mr. Tse started to develop his investment and business in China. He has been engaged in the pharmaceutical industry since 1991, having made equity investments in a dozen or so enterprises, and is one of the most successful overseas investors in the PRC pharmaceutical industry. Led by Mr. Tse, CP Pharmaceutical Group has developed to a large integrated life and healthcare enterprise, and its Hong Kong listed flagship Sino Biopharmaceutical Limited is a constituent of the Heng Seng Index, holding a leading position among pharmaceutical stocks in the market and owning a number of national key high-technology enterprises. Adhering to the concept of technology innovation and building upon R&D system based on originality as well as imitation, the Group strives to develop international level, high-end biological drugs and innovative drugs and to achieve breakthroughs in different areas including medical services, medical equipment, the greater health fields, and mergers and acquisitions, and becomes an innovation driven life and healthcare enterprise with its business encompassing the entire industry chain which spans from R&D to manufacture and sales of pharmaceutical products and covers management of chronic diseases and healthcare. Since incorporation, the Company continues to break its own record in terms of revenue and net profit, and was ranked one of the “Asia's Fab 50 Companies” by Forbes Asia for three consecutive years from 2016 to 2018 and was included in American Magazine Pharm Exec's “Top 50 Companies” for two consecutive years in 2019 and 2020.


As a recognition for his efforts in promoting the development of the pharmaceutical industry in China, Mr. Tse was awarded a number of honours, including the prize of “World Outstanding Chinese” and an honorary Doctor Degree by the University of West Alabama, United States of America in January, 2008, and the “2007/2008 Asian Knowledge Management Association academician” granted by the Asian Knowledge Management Association in December, 2008.


Mr. Tse was a member of the Ninth, Tenth and Eleventh National Committee of the Chinese People's Political Consultative Conference. He is currently an executive vice chairman of the China Federation of Overseas Chinese Entrepreneurs and a distinguished professor of University for Peace, UPEACE.